Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase III
Recipient : Daegu Catholic University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 02, 2022
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Recipient : Daegu Catholic University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Study Phase : Phase IV
Recipient : Korea University Guro Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Anesthesia Induction With Intravenous Bolus or Continuous Infusion of Remimazolam
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Recipient : Korea University Guro Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Kangbuk Samsung Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Quality of Recovery of Remimazolam Versus Sevoflurane in Transurethral Bladder Resection.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Kangbuk Samsung Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BOLD-100,Fluorouracil,Oxaliplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Bold Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Preclinical experiments have repeatedly shown that BOLD-100 improves outcomes in combination with a wide range of existing anti-cancer therapies, with particular synergy evident in drug-resistant cell lines.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 13, 2022
Lead Product(s) : BOLD-100,Fluorouracil,Oxaliplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Bold Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BOLD-100
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Bold Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under this agreement, Bold Therapeutics and Hana Pharm will collaborate on Bold Therapeutics’ upcoming Phase 1b / 2a adaptive trial in gastric, pancreatic, colorectal, and bile duct cancers – and explore the potential development of BOLD-100 in tripl...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 27, 2020
Lead Product(s) : BOLD-100
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Bold Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2011
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable